Tubulis' suite of proprietary platform technologies generates uniquely matched antibody-drug conjugates with superior biophysical properties for treating solid tumors

By demonstrating durable on-tumor delivery of the payload and long-lasting anti-tumor activity, we have reached the clinic with our first program, TUB-040, in ovarian and non-small cell lung cancer. The second candidate from our growing pipeline, TUB-030, is set to follow in the near-term. We will solidify our leadership position by continuing to innovate on all aspects of ADC design to expand their therapeutic potential for our pipeline, our partners and for patients.

Our technology

The Tubulis Approach: A broad technology suite to expand the treatment horizon of ADCs

Our Pipeline

The Tubulis Pipeline: Innovative ADC candidates for solid and hematologic tumors


Meet Tubulis live